Digital disruption, novel therapies and treatments, dynamic new technological advancements, health equity and more – all in focus for CNBC’s Healthy Returns. Join us for this online forum, March 29th.
CNBC’s Healthy Returns convenes the sharpest minds, bold pioneers and visionary leaders in the health care industry on what they see ahead for treatments and innovations, what’s working, what needs to improve, and what’s on the horizon that will shape health care for the future.
WHO SHOULD ATTEND: Health care investors, VCs, C-Suite executives from the biotech, pharma, health care and life sciences industries, health care IT BDMs.
Rosalind (Roz) Brewer joined Walgreens Boots Alliance as Chief Executive Officer in March 2021. She also is a Director on WBA’s Board. Ms. Brewer most recently served as Chief Operating Officer and Group President at Starbucks from October 2017 to January 2021. Prior to Starbucks, she served as President and Chief Executive Officer of Sam’s Club, a membership-only retail warehouse club and division of Walmart, Inc., from February 2012 to February 2017. Ms. Brewer previously held several executive leadership positions with Walmart beginning in 2006.
Prior to joining Walmart, she served as President of Global Nonwovens Division for Kimberly-Clark Corporation, a global health and hygiene products company, from 2004 to 2006, and held various management positions at Kimberly-Clark beginning in 1984.
She currently serves as the Chairperson of the Board of Trustees for Spelman College, where she did her undergraduate work. Ms. Brewer also is a Board Member of VillageMD, World Business Chicago, Business Roundtable and the Smithsonian’s National Museum of African-American History and Culture. Ms. Brewer formerly served on the Board of Directors for Starbucks, Amazon, Lockheed Martin Corporation and Molson Coors Brewing Company. She is currently ranked #6 on Fortune’s 50 Most Powerful Women in Business and was named one of the 25 most influential women by the Financial Times in 2021.
Joaquin Duato is the Chief Executive Officer of Johnson & Johnson and serves on its Board of Directors. As CEO of the world’s largest healthcare company, Joaquin leads a global workforce of 135,000 employees in developing and delivering transformational and innovative healthcare solutions in Pharmaceuticals, MedTech, and Consumer Health.
From his early days in Spain, Joaquin found inspiration by focusing on how healthcare improved patients’ lives. Over the course of three decades with the company, he developed a deep understanding of what’s possible at Johnson & Johnson by working in all business sectors and across multiple geographies and functions. Before being named CEO, Joaquin served as the Vice Chairman of the Executive Committee, where he provided strategic direction for the Pharmaceutical and Consumer Health sectors and oversaw both Information Technology and the Global Supply Chain.
Joaquin’s many accomplishments include driving the transformation of the company’s pharmaceutical business into a global powerhouse by refocusing strategy and investment around core therapeutic areas and areas of greatest unmet need during his tenure as the sector’s Worldwide Chairman. More recently, he oversaw the company’s rapid response to the COVID-19 pandemic and drove coordination of global initiatives to safeguard the health of employees and ensure business and supply chain continuity, so the company’s life-saving medicines and products reached patients and communities in need.
A believer in the power of technology to accelerate progress in healthcare, Joaquin is leading Johnson & Johnson to harness data science and intelligent automation for insight generation so that teams work as a united front, with expertise and purpose, to solve the world’s toughest health challenges.
A dual citizen of Spain and the United States, Joaquin’s international perspective gives him a deep appreciation of diversity in all its forms. He is committed to building an inclusive workforce that reflects the patients J&J serves, evidenced by nearly a decade acting as Executive Sponsor for the African Ancestry Leadership Council ERG.
Joaquin earned an MBA from ESADE in Barcelona, Spain, and a Master of International Management from Thunderbird School of Global Management in Phoenix, Arizona. He lives in Pennsylvania with his wife and two college-aged children.
Dr. Brown graduated from Yale College, where she majored in molecular biophysics and biochemistry. She earned her medical degree from Harvard University. She completed internship and residency programs in medicine at Vanderbilt University, where she also did a fellowship in clinical pharmacology. Dr. Brown joined the faculty of Vanderbilt in 1992 and held a number of leadership positions, serving as chief of the Division of Clinical Pharmacology, associate dean for clinical and translational scientist development, and Robert H. Williams professor before becoming the Hugh J. Morgan Chair of Medicine and physician-in-chief of Vanderbilt University Hospital in 2010.
In 2020, she became Jean and David W. Wallace Dean of Medicine and C.N.H. Long Professor of Internal Medicine at Yale School of Medicine. Dr. Brown has long been committed to medical education and mentorship. At Vanderbilt, she established the Elliot Newman Society to support the development of physician-scientists and co-founded the Vanderbilt Master of Science in Clinical Investigation program. Her research has defined the molecular mechanisms through which commonly prescribed blood pressure and diabetes drugs affect the risk of cardiovascular and kidney disease. In her clinical practice, she has treated patients with resistant and secondary forms of hypertension. Dr. Brown has served as a member of the NIH National Advisory Research Resources Council and the National Heart, Lung, and Blood Advisory Council. She was president of the Association of Professors of Medicine. In 2019, she was elected a Master of the American College of Physicians.Her numerous awards include election to the American Society for Clinical Investigation, the Association of American Physicians, and the National Academy of Medicine. She is a member of the American Association of Arts and Sciences.
World-renowned cardiologist Dr. Henry Ting joined Delta Air Lines in 2021 as the global brand’s Chief Health Officer – a first for a U.S. airline. In his most recent role as Mayo Clinic’s enterprise Chief Value Officer, Dr. Ting became familiar with Delta both as a long-time Medallion customer and, more recently, as a primary COVID-19 advisor who has helped shape Delta’s response since the early days of the pandemic.
From employee testing and cleanliness strategies to operational tactics that reduce the transmission of the virus, Dr. Ting has been a key voice in the health and wellness decisions that have helped Delta strengthen the people-first approach we were known for even prior to the pandemic. As part of the Delta team, Dr. Ting is building on this work to help Delta navigate the pandemic and emerge stronger and better prepared for the future.
Working collaboratively with groups across the airline, Dr. Ting leads Delta in reimagining our approach to health and well-being, utilizing new technologies, artificial intelligence, advanced analytics and innovative partnerships.
In addition to his role at Delta, Dr. Ting retains his title as Professor Emeritus at Mayo Clinic.
Before joining Delta, Dr. Ting served in multiple leadership roles at Mayo Clinic including enterprise Chief Value Officer, clinical practice Chair of the Department of Cardiology and Associate Dean. He also served as S.V.P. and Chief Quality Officer at New York Presbyterian Hospital.
Dr. Ting’s academic focus includes health services research, outcomes research and implementation science. He has lectured worldwide and authored over 200 journal articles, book chapters and publications. In addition, he has served on committees and boards for the U.S. Department of Health and Human Services, U.S. Agency for Healthcare Research and Quality, National Quality Forum and U.S. News & World Report advisory council.
Dr. Ting received his bachelor’s degree in chemistry from Cornell University, Doctorate of Medicine from Harvard Medical School and master’s degree in business administration from the University of St. Thomas.